Fig. 3From: A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolizationComparisons of the AUROC values for the survival status between the inflammation-based prognostic scores and the staging systems at overall survive. a 1 (b), 3 (c), and 5-years (d)Back to article page